Huimin completed her master's degree at the University of Sydney on the topic of Development of novel targeted drug delivery systems to prevent and treat breast cancer bone metastasis and she has background in both nanotechnology and cancer research. Currently, she is pursuing her PhD at South Australian Immunogenomics Cancer Institute (SAIGENCI), focusing on the cross-talking of cancer-related signalling pathways and the development of potential treatment targets.